[PDF][PDF] Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
B Pro, R Advani, P Brice, NL Bartlett, JD Rosenblatt… - J Clin Oncol, 2012 - Citeseer
J Clin Oncol, 2012•Citeseer
Purpose Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell
lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate
brentuximab vedotin delivers the potent antimicrotubule agent monomethylauristatin E to
CD30-positive malignant cells. A phase II multicenter trial was conducted to evaluate the
efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic
ALCL.
lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate
brentuximab vedotin delivers the potent antimicrotubule agent monomethylauristatin E to
CD30-positive malignant cells. A phase II multicenter trial was conducted to evaluate the
efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic
ALCL.
Purpose
Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate brentuximab vedotin delivers the potent antimicrotubule agent monomethylauristatin E to CD30-positive malignant cells. A phase II multicenter trial was conducted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic ALCL.
Citeseer